Emily Sims

47PUBLICATIONS
182CO-AUTHORS
AutoimmunityPredictive and prognostic markersBehavioural epidemiologyOther commerce, management, tourism and services not elsewhere classifiedGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (47)

|May 15, 2026
US Patterns in Clinical Islet Autoantibody Ordering and Results Show Key Differences After Teplizumab Regulatory Approval.

|Apr 30, 2026
C-Peptide Provides Critical Contextual Insight Into Elevated Glucose Values During Progression to Type 1 Diabetes.

|Feb 27, 2026
Accounting for age-related increases in HbA1c more accurately quantifies risk of Type 1 Diabetes progression in islet autoantibody-positive adults.

Erin L Templeman, Nick Thomas, Susan Martin

|Feb 23, 2026
Assessing extracellular vesicle proteins as predictive biomarkers for developing type 1 diabetes.

Panshak P Dakup, Lisa M Bramer, Athena Schepmoes

|Feb 20, 2026
Going From Stage 2 to Stage 3 Type 1 Diabetes-Does Not Matter How You Got Here.

Laura M Jacobsen, Emily K Sims

|Nov 06, 2025
Toward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab.

Chantal Mathieu, Emily K Sims, Lucienne Chatenoud

Pageof 8

Frequent Collaborators

10 joint publications

Raghavendra G Mirmira

10 joint publications

Heba M Ismail

9 joint publications

Carla J Greenbaum

9 joint publications

Carmella Evans-Molina